Cardiome Pharma Corp. (USA) (NASDAQ:CRME)

CAPS Rating: 3 out of 5

Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.

Recs

0
Player Avatar Lcrazylegs84 (< 20) Submitted: 9/17/2011 6:33:57 PM : Outperform Start Price: $3.66 CRME Score: -98.49

going going up

Featured Broker Partners


Advertisement